A review of antidepressant-induced hypomania in major depression: Suggestions for DSM-V

Bipolar Disorders

Volumn 6, Issue 1, 2004, Pages 32-42

  Chun, Benjamin J D H ^a   Dunner, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antidepressants; Bipolar disorder; Depression; Hypomania

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; HETEROCYCLIC COMPOUND; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BIPOLAR MANIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC ERROR; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUPHORIA; FREQUENCY ANALYSIS; HUMAN; HYPOMANIA; INCIDENCE; MAJOR DEPRESSION; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS; DEPRESSIVE DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS;

EID: 1342311506     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-5618.2003.00084.x     Document Type: Review

References (134)

1. Krauthammer C, Klerman GL. Secondary mania: manic syndromes associated with antecedent physical illness or drugs. Arch Gen Psychiatry 1978; 35: 1333-1339.
2. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987; 144: 1403-1411.
3. Physicians' Desk Reference, 56th edn. Montvale, NJ: Medical Economics Company, Inc., 2002.
4. Beasley CM, Jr, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991; 52: 294-299.
5. Levinson ML, Lipsy RJ, Fuller DK. Adverse effects and drug interactions associated with fluoxetine therapy. DICP 1991; 24: 62-67.
6. Jerome L. Hypomania with fluoxetine. J Am Acad Child Adolesc Psychiatry 1991; 30: 850-851.
7. Venkataraman S, Naylor MW, King CA. Mania associated with fluoxetine treatment in adolescents. J Am Acad Child Adolesc Psychiatry 1992; 31: 276-281.
8. Jafri AB, Greenberg WM. Fluoxetine side effects. J Am Acad Child Adolesc Psychiatry 1991; 30: 852.
9. Ramasubbu R. Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders. Acta Psychiatr Scand 2001; 104: 236-239.
10. Laporta M, Chouinard G, Goldbloom D, Beauclair L. Hypomania induced by sertraline, a new serotonin reuptake inhibitor. Am J Psychiatry 1987; 144: 1513-1514.
11. Benazzi F. Organic hypomania secondary to sibutramine-citalopram interaction. J Clin Psychiatry 2002; 63: 165.
12. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549-550.
13. Waslick BD, Walsh BT, Greenhill LL, Eilenberg M, Capasso L, Lieber D. Open trial of fluoxetine in children and adolescents with dysthymic disorder or double depression. J Affect Disord 1999; 56: 227-236.
14. Hellerstein DJ, Yanowitch P, Rosenthal J et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 1993; 150: 1169-1175.
15. Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998; 10: 145-150.
16. Nobler MS, Devanand DP, Kim MK et al. Fluoxetine treatment of dysthymia in the elderly. J Clin Psychiatry 1996; 57: 254-256.
17. Diaz-Martinez A, Benassinni O, Ontiveros A et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 1998; 20: 467-476.
18. Aguglia E, Casacchia M, Cassano GB et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8: 197-202.
19. Beasley CM, Jr, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry 1993; 5: 199-207.
20. Nielsen BM, Behnke K, Arup P et al. A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr Scand 1993; 87: 269-272.
21. Beasley CM, Jr, Nilsson ME, Koke SC, Gonzales JS. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a metaanalysis of the 20-mg/day dose. J Clin Psychiatry 2000; 61: 722-728.
22. Patris M, Bouchard JM, Bougerol T et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996; 11: 129-136.
23. De Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87: 141-145.
24. Beasley CM, Jr, Sayler ME, Potvin JH. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. Int Clin Psychopharmacol 1993; 8: 143-149.
25. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999; 56: 171-181.
26. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998; 59: 352-357.
27. Wheatley DP, van Moffaert M, Timmerman L, Kremer CM. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-fluoxetine study group. J Clin Psychiatry 1998; 59: 306-312.
28. Gilaberte I, Montejo AL, de la Gandara J et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001; 21: 417-424.
29. Beasley CM, Jr, Koke SC, Nilsson ME, Gonzales JS. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther 2000; 22: 1319-1330.
30. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 study group. J Clin Psychiatry 1999; 60: 22-28.
31. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord 1998; 48: 47-56.
32. Lewis-Hall FC, Wilson MG, Tepner RG, Koke SC. Fluoxetine vs tricyclic antidepressants in women with major depressive disorder. J Womens Health 1997; 6: 337-343.
33. Lapierre YD, Joffe R, McKenna K et al. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. J Psychiatry Neurosci 1997; 22: 118-126.
34. Duarte A, Mikkelsen H, Delini-Stula A. Moclobemide versus fluoxetine for double depression: a randomized double-blind study. J Psychiatr Res 1996; 30: 453-458.
35. Reynaert C, Parent M, Mirel J, Janne P, Haazen L. Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology (Berl.) 1995; 118: 183-187.
36. Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13 (Suppl. 2): 34S-39S.
37. Feighner JP, Gardner EA, Johnston JA et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991; 52: 329-335.
38. de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991; 24: 62-67.
39. Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 2002; 22: 137-147.
40. Claghorn JL, Earl CQ, Walczak DD et al. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996; 16: 113-120.
41. Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997; 58: 146-152.
42. Ware MR. Fluvoxamine: a review of the controlled trials in depression. J Clin Psychiatry 1997; 58 (Suppl. 5): 15-23.
43. Findling RL, Reed MD, Myers C et al. Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38: 952-959.
44. Ballus C, Quiros G, De Flores T et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000; 15: 43-48.
45. Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM, Jr. The Mirtazapine Vs Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10: 541-550.
46. Cassano GB, Jori MC. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2002; 17: 27-32.
47. Moon CA, Vince M. Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramide. Br J Clin Pract 1996; 50: 240-244.
48. Dunbar GC, Claghorn JL, Kiev A, Rickels K, Smith WT. A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand 1993; 87: 302-305.
49. Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C. A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta Psychiatr Scand Suppl 1989; 350: 117-123.
50. Szegedi A, Wetzel H, Angersbach D et al. A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry 1997: 30: 97-105.
51. Weihs KL, Settle EC, Jr, Batey SR, Houser TL, Donahue RM, Ascher JA. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000; 61: 196-202.
52. Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dube EM. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002; 63: 577-584.
53. Baldwin DS, Hawley CJ, Abed RT et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996; 57 (Suppl. 2): 46-52.
54. Duboff EA. Long-term treatment of major depressive disorder with paroxetine. J Clin Psychopharmacol 1993; 13 (Suppl. 2): 28S-33S.
55. Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC. Paroxetine versus placebo: a double-blind comparison in depressed patients. J Clin Psychiatry 1992; 53: 434-438.
56. Thase ME, Fava M, Halbreich U et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996; 53: 777-784.
57. Keller MB, Gelenberg AJ, Hirschfeld RMA et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998; 59: 598-607.
58. Forlenza OV, Almeida OP, Stoppe A, Jr, Hirata ES, Ferreira RCR. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Int Psychogeriatr 2001; 13: 75-84.
59. Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997; 12: 323-331.
60. Mehtonen OP, Sogaard J, Roponen P, Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 study group. J Clin Psychiatry 2000; 61: 95-100.
61. Moller HJ, Gallinat J, Hegerl U et al. Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Pharmacopsychiatry 1998; 31: 170-177.
62. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997; 58: 532-537.
63. Lydiard RB, Stahl SM, Hertzman M, Harrison WM. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997; 58: 484-491.
64. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996; 57 (Suppl. 2): 53-62.
65. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in patients with major depression. J Clin Psychiatry 1995; 56: 229-237.
66. Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry 2000; 61: 821-827.
67. Moller HJ, Glaser K, Leverkus F. Gobel C. Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression. Pharmacopsychiatry 2000; 33: 206-212.
68. Rosenberg C, Damsbo N, Fuglum E, Jacobsen LV, Horsgard S. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int Clin Psychopharmacol 1994; 9 (Suppl. 1): 41-48.
69. Leionen E, Skarstein J, Behnke K, Agren H, Helsdingen JT. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic antidepressant study group. Int Clin Psychopharmacol 1999; 14: 329-337.
70. Barak Y, Kimhi R, Weizman R. Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients? Int Clin Psychopharmacol 2000; 15: 53-56.
71. Kyle CJ, Petersen HE, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8: 147-153.
72. Feighner JP, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 1999; 60: 824-830.
73. Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord 1997; 46: 73-77.
74. Keller MB, McCullough JP, Klein DN et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342: 1462-1470.
75. Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother 1995; 29: 387-395.
76. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitritpyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 63-73.
77. Hoyberg OJ, Maragakis B, Mullin J et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996; 93: 184-190.
78. Ansseau M, Darimont P, Lecoq A et al. Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology (Berl.) 1994; 115: 254-260.
79. Bakish D, Bradwejn J, Nair N, McClure J, Remick R, Bulger L. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl.) 1992; 106 (Suppl.): 98-101.
80. Rabkin JG, Quitkin FM, McGrath P, Harrison W, Tricamo E. Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management. J Clin Psychopharmacol 1985; 5: 2-9.
81. Kupfer DJ, Carpenter LL, Frank E. Possible role of antidepressants in precipitating mania and hypomania in recurrent depression. Am J Psychiatry 1988; 145: 804-808.
82. Woelk H. Comparison of St. John's wort and imipramine for treating depression: randomized controlled trial. BMJ 2000; 321: 536-539.
83. Baumhackl U, Biziere K, Fischbach R et al. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study. Br J Psychiatry Suppl 1989; 6: 78-83.
84. Versiani M, Oggero U, Alterwain P et al. A double-blind comparative trial of moclobermide v. imipramine and placebo in major depressive episodes. Br J Psychiatry Suppl 1989; 6: 72-77.
85. Shrivastava RK, Cohn C, Crowder J et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994; 14: 322-329.
86. Katona C, Bercoff E, Chin E, Tack P, Versiani M, Woelk H. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomized trial. J Affect Disord 1999; 55: 203-213.
87. Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S. Selective and nonselective monoamine oxidase inhibitors. Arch Gen Psychiatry 1982; 39: 535-540.
88. Remick RA, Froese C, Keller FD. Common side effects associated with monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 497-504.
89. Cohen RM, Pickar D, Murphy DL. Myoclonus-associated hypomania during MAO-inhibitor treatment. Am J Psychiatry 1980; 137: 105-106.
90. Pickar D, Cohen R. Implications of monoamine oxidase inhibitor-induced hypomania. Arch Gen Psychiatry 1978; 35: 1393-1394.
91. Goldman LS, Tiller JA. Hypomania related to phenelzine and isoetharine interaction in one patient. J Clin Psychiatry 1987; 48: 170.
92. Jabeen S, Fisher CJ. Trazodone-induced transient hypomanic symptoms and their management. Br J Psychiatry 1991; 158: 275-278.
93. Lennhoff M. Trazodone-induced mania. J Clin Psychiatry 1987; 48: 423-424.
94. Mann JJ. A controlled study of trazodone, imipramine and placebo in outpatients with endogenous depression. J Clin Psychopharmacol 1981; 1: 75-80.
95. Weihs KL, Houser TL, Batey SR et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002; 51: 753-761.
96. Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999; 21: 454-463.
97. Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin Ther 1998; 20: 505-516.
98. Lineberry CG, Johnston JA, Raymond RN et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 1990; 51: 194-199.
99. Rouillon F, Serrurier D, Miller HD, Gerard M. Prophylactic efficacy of maprotiline on unipolar depression relapse. J Clin Psychiatry 1991; 52: 423-431.
100. Vaz-Serra A, Figueira ML, Firmino H, Albuquerque AJ, Jara JM, Pestana LC. Multicenter double-blind study of moclobemide and maprotiline. Clin Neuropharmacol 1994; 17 (Suppl. 1): S38-S49.
101. Dunner DL, Hendrickson HE, Bea C, Budech CB, O'Connor E. Dysthymic disorder: treatment with mirtazapine. Depress Anxiety 1999; 10: 68-72.
102. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21: 425-431.
103. Fava M, Dunner DL, Greist JH et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001; 62: 413-420.
104. Thase ME, Nierenberg AA, Keller MB, Panagides J. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-contro lied double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001; 62: 782-788.
105. Soutullo CA, McElroy SL, Keck PE, Jr. Hypomania associated with mirtazapine augmentation of sertraline. J Clin Psychiatry 1998; 59: 320.
106. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995; 10 (Suppl. 2): 15-20.
107. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996; 16 (Suppl. 2): 54S-61S.
108. Joffe RT, Marshall AM, Lee DK. A large open-label study of venlafaxine in depressed outpatients by community-based physicians. J Clin Psychiatry 1998; 59: 515-520.
109. Dunner DL, Hendrickson HE, Bea C, Budech CB. Venlafaxine in dysthymic disorder. J Clin Psychiatry 1997; 58: 528-531.
110. Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 2000; 59: 225-229.
111. de Montigny C, Silverstone PH, Debonnel G, Blier P, Bakish D. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999; 19: 401-406.
112. Ravindran AV, Charbonneau Y, Zaharia MD, al-Zaid K, Wiens A, Anisman H. Efficacy and tolerability of venlafaxine in the treatment of primary dysthymia. J Psychiatry Neurosci 1998; 23: 288-292.
113. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998; 59: 116-122.
114. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The venlafaxine XR 209 study group. J Clin Psychiatry 1997; 58: 393-398.
115. Kocsis JH, Friedman RA, Markowitz JC et al. Maintenance therapy for chronic depression: a controlled clinical trial of desipramine. Arch Gen Psychiatry 1996; 53: 769-774.
116. Angst J. Switch from depression to mania - a record study over decades between 1920 and 1982. Psychopathology 1985; 18: 140-154.
117. Leyberg JT, Denmark JC. The treatment of depressive states with imipramine hydrochloride (Tofranil). J Ment Sci 1959; 105: 1123-1126.
118. McElroy SL, Keck PE, Friedman LM. Minimizing and managing antidepressant side effects. J Clin Psychiatry 1995; 56 (Suppl. 2): 49-55.
119. Lewis JL, Winokur G. The induction of mania: a natural history study with controls. Arch Gen Psychiatry 1982; 39: 303-306.
120. Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001; 62: 249-255.
121. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000; 61: 804-808.
122. Amsterdam JD, Garcia-Espana F, Fawcett J et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998; 18: 435-440.
123. Howland RH. Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 1996; 16: 425-427.
124. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000; 59 (Suppl. 1): S5-S30.
125. Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin FK. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord 1999; 52: 135-144.
126. Coryell W, Endicott J, Maser JD, Keller MB, Leon AC, Akiskal HS. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995; 152: 385-390.
127. Bowden CL. Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv 2001; 52: 51-55.
128. Steele TE, Taylor CI. Hypomania and tricyclic antidepressant choice. Am J Psychiatry 1980; 137: 1457-1458.
129. Akiskal HS, Mallya G. Criteria for the "soft" bipolar spectrum: treatment implications. Psychopharmacol Bull 1987; 23: 68-73.
130. Akiskal HS, Maser JD, Zeller PJ et al. Switching from "unipolar" to bipolar II: an 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 1995; 52: 114-123.
131. Dunner DL, Fleiss JL, Fieve RR. The course of development of mania in patients with recurrent depression. Am J Psychiatry 1976; 133: 905-908.
132. Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am J Psychiatry 2001; 158: 1265-1270.
133. Danner DL, Tay LK. Diagnostic reliability of the history of hypomania in bipolar II patients and patients with major depression. Compr Psychiatry 1993; 34: 303-307.
134. Hantouche EG, Akiskal HS, Lancrenon S et al. Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord 1998; 50: 163-173.